Previous studies indicated that the chloro-benztropine analogs differed significantly in their cocaine-like activity, which was not expected based on the similarity in their in vitro binding affinity and functional potency at the dopamine transporter (DAT). The present study was designed to extend the understanding of the involvement of both pharmacokinetic and pharmacodynamic factors in mediating the behavioral differences among these analogs. The pharmacokinetics of 3Ј-chloro-3␣-(diphenylmethoxy)tropane (3Ј-Cl BZT), the analog showing a cocaine-like behavioral profile in rodents, was compared with previously reported pharmacokinetic characteristics of cocaine and 4Ј,4Љ-dichloro-3␣-(diphenylmethoxy)tropane (4Ј,4Љ-diCl BZT), an analog totally devoid of cocaine-like actions. Microdialysis studies in rats were conducted to determine whether 3Ј-Cl and 4Ј,4Љ-diCl BZT differed significantly in their effect on nucleus accumbens extracellular dopamine levels, with cocaine serving as a reference. A mechanistic model based on DAT association/ dissociation kinetics was used to describe the time delay between the plasma concentrations of the chloro-analogs and their dopaminergic effects. 3Ј-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4Ј,4Љ-diCl BZT, respectively. 4Ј,4Љ-diCl BZT increased the DA levels at a slower rate and to a significantly lower extent relative to 3Ј-Cl BZT that were, in turn, lower than cocaine. The duration of dopamine elevation was as follows: 4Ј,4Љ-diCl BZT Ͼ 3Ј-Cl BZT Ͼ cocaine. The model indicated faster association and dissociation with DAT for 3Ј-Cl BZT relative to 4Ј,4Љ-diCl BZT. The present results indicate that behavioral differences among the chloro-analogs may be explainable based on both the dopamine and rate hypotheses of drug abuse.
Substantial evidence has accumulated over the years in favor of the dopamine (DA) hypothesis of cocaine abuse (Ritz et al., 1987; Kuhar et al., 1991; Volkow et al., 1997) . According to this hypothesis, the ability of cocaine to block the dopamine transporter (DAT) and to inhibit DA uptake, which results in increased dopaminergic neurotransmission in the mesolimbic and mesocortic systems, is the critical element in mediating the reinforcing and psychostimulant effects of cocaine.
The benztropine (BZT) analogs are potent and selective DA uptake inhibitors (Newman et al., 1994 (Newman et al., , 1995 Katz et al., 1999) . However, they are generally weak psychostimulants and weak reinforcers relative to cocaine in animal models of drug abuse Woolverton et al., 2001 ). In addition, the BZT analogs have shown gradations in their cocaine-like activities that are not matched by significant gradations in their in vitro affinity to DAT or in their potency as DA uptake inhibitors. For example, two studies indicated that 3Ј-chloro-3␣-(diphenylmethoxy)tropane (3Ј-Cl BZT) significantly substituted for cocaine in rats trained to discriminate cocaine from saline (Kline et al., 1997; Katz et al., 2001) . Conversely, neither 4Ј-chloro-3␣-(diphenylmethoxy)tropane (4Ј-Cl BZT) nor 4Ј,4Љ-dichloro-3␣-(diphenylmethoxy)tropane (4Ј,4Љ-diCl BZT) produced any cocaine substitution greater than saline (Kline et al., 1997; Katz et al., 2001 ). In addition, the chloro-analogs demonstrated reduced locomotor stimulant activity in mice relative to cocaine. However, 4Ј-Cl and 3Ј-Cl BZT were the closest to cocaine in terms of maximal stimulation during the 1st hour of administration followed by 3Ј,4Љ-dichloro-3␣-(diphenylmethoxy) tropane (3Ј,4Љ-Cl BZT) followed by 4Ј,4Љ-diCl BZT, which minimally stimulated the locomotor activity in mice . Moreover, the chloro-analogs differed significantly in their reinforcing efficacies in self-administration studies in rhesus monkeys, with the following rank order relative to cocaine: cocaine Ͼ 3Ј-Cl BZT ϭ 4Ј-Cl BZT Ͼ Ͼ 3Ј,4Љ-diCl BZT . The behavioral differences of the chloro-BZT analogs (compared with one another and with cocaine) seems to challenge the dopamine hypothesis given that these analogs ( Fig. 1 ) possess comparable affinities and potencies at DAT that are higher than cocaine (DAT K i range, 20 -32.5 versus 187 nM for cocaine; and DA uptake inhibition IC 50 range, 12.3-23.4 versus 236 nM for cocaine) . Recently, several studies focused on characterizing the mechanisms underlying the behavioral differences of the BZT analogs (Campbell et al., 2005; Desai et al., 2005a; Tanda et al., 2005 Tanda et al., . 2007 Othman et al., 2007) . Such characterization could have important implications for successful design of substitute pharmacotherapies for treatment of cocaine abuse that should share the mechanism of action of cocaine without sharing its high abuse potential.
The rate and extent of brain entry, rate of occupancy of DAT, and/or rate of elevation of extracellular DA level, as well as extent and duration of DA elevation, are all critical factors in determining the abuse liability of DA uptake inhibitors (Volkow et al., 1995; Quinn et al., 1997; Gorelick, 1998 Gorelick, , 2000 Gorelick, , 2005 . Previous pharmacokinetic studies from our laboratory in rats for cocaine, 4Ј-Cl, and 4Ј,4Љ-diCl BZT (Raje et al., 2003; Othman et al., 2007) indicated that 1) the brain uptake of the chloro-analogs was comparable and higher than that of cocaine excluding the extent of brain exposure as a factor mediating the behavioral differences; 2) there was no time delay in brain entry of 4Ј-Cl BZT or 4Ј,4Љ-diCl BZT in comparison with cocaine; and 3) the rank order for the plasma and brain elimination half-lives was the reverse of the differences in abuse liability, i.e., 4Ј,4Љ-diCl BZT Ͼ Ͼ 4Ј-Cl BZT Ͼ cocaine.
The present study was designed to extend our understanding of the involvement of the pharmacokinetic and pharmacodynamic factors in mediating the differences in the behavioral pharmacology of the chloro-BZT analogs. Specifically, we wanted to 1) evaluate the pharmacokinetics and brain uptake of 3Ј-Cl BZT, the analog that has more consistently demonstrated cocaine-like effects in rodents and that may have higher abuse potential than the other chloro-BZT analogs; and 2) evaluate whether 3Ј-Cl and 4Ј,4Љ-diCl BZT, two analogs representative of the extremes of the behavioral spectrum of the chloro-series, differ qualitatively and/or quantitatively in their effect on nucleus accumbens (NAc) DA level in terms of rate, extent, and duration of elevation. In addition, this study was designed to characterize the quantitative relationship between the plasma concentrations of the chloro-analogs and their effects on NAc DA level using a mechanistic population pharmacodynamic modeling approach that models the effect on the NAc DA level as a function of the binding kinetics to DAT.
Materials and Methods

Materials
Cocaine HCl, xylazine, dopamine HCl, EDTA, octyl sulfate sodium salt, (2-hydroxypropyl)-␤-cyclodextrin, and sodium phosphate dibasic were purchased from Sigma-Aldrich (St. Louis, MO). Monochloroacetic acid was purchased from J. T. Baker (Phillipsburg, NJ). Sodium hydroxide was purchased from American Bioanalytical (Natick, MA). Potassium monobasic phosphate and potassium dibasic phosphates were purchased from Fisher Scientific Co. (Fair Lawn, NJ) . Artificial cerebrospinal fluid (aCSF) containing 150 mM sodium, 3.0 mM potassium, 1.4 mM calcium, 0.8 mM magnesium, 1.0 mM phosphorus, and 155 mM chloride were purchased from Harvard Apparatus Inc. (Holliston, MA). Ketamine HCl injection was purchased from Bedford Laboratories (Bedford, OH). Methohexital (brevital sodium) was purchased from Henry Schein (Port Washington, NY). 3Ј-Cl BZT HCl, 4Ј-Cl BZT HCl, and 4Ј,4Љ-diCl BZT HBr were synthesized in the Medicinal Chemistry Section (National Institute on Drug Abuse-Intramural Research Program, Baltimore, MD) as described previously (Newman et al., 1994 (Newman et al., , 1995 Kline et al., 1997) . All chemicals and solvents were high-performance liquid chromatography (HPLC) grade or American Chemical Society analytical grade.
Animals
Adult male Sprague-Dawley rats (250 -350 g) were used in the pharmacokinetic and microdialysis studies. They were purchased from Harlan (Indianapolis, IN). The study protocols were approved by the Institutional Animal Care and Use Committee of the School of Pharmacy (University of Maryland, Baltimore). Rats were housed in the animal facility at a room temperature of 23 Ϯ 1°C. They were allowed free access to food (Purina 5001 Rodent Chow; Purina, St. Louis, MO) and water ad libitum, and they were maintained on a 12-h light/dark cycle (light on from 7:00 AM to 7:00 PM). 
Dosing Solutions
3Ј-Cl BZT HCl, 4Ј,4Љ-diCl BZT HBr, and cocaine HCl were dissolved in 20% (2-hydroxypropyl)-␤-cyclodextrin in sterile water for injection. The dosing for the pharmacokinetic and microdialysis studies was conducted at a volume of 1 ml/kg and at a dose of the free base equivalent to 5 or 10 mg/kg of the hydrochloride salt.
3-Cl BZT Pharmacokinetic Study
The rats were administered 3Ј-Cl BZT at an i.v. dose of 5 or 10 mg/kg. A destructive sampling design was adapted where groups of three animals were sacrificed by CO 2 asphyxiation predose and postdose at 5, 30, 60, 120, 240, 360, 480 , and 600 min. Blood was collected by heart puncture using heparinized syringes, and the blood was centrifuged for 10 min at 3000 rpm. The plasma was separated and stored at Ϫ80°C until the analysis. Brain tissues were immediately removed, blotted on a filter paper, weighed, and stored at Ϫ80°C until the time of analysis.
Analysis of the Pharmacokinetic Samples
A previously published UV-HPLC method with few modifications was used for analysis of 3Ј-Cl BZT (Raje et al., 2002) . The chromatographic conditions consisted of a Symmetry C18 column (150 ϫ 4.6 mm; 5 m; Waters, Milford, MA), UV detector ( ϭ 220 nm), mobile phases [methanol/0.05 M Na 2 HPO 4 , pH 3.0, 40:60 (v/v) (A) and methanol/0.05 M Na 2 HPO 4 , pH 3.0, 80:20 (v/v) (B)], and a flow rate of 1 ml/min pumped using an isocratic profile (55% solvent A and 45% solvent B). The plasma samples were extracted with hexane followed by evaporation and reconstitution in the mobile phase. The brain samples were double extracted with hexane following homogenization with distilled water. 4Ј-Cl BZT was used as an internal standard for analysis of 3Ј-Cl BZT without any interference. The calibration curves were linear (r 2 Ն 0.999) in the range of 25 to 5000 ng/ml and 100 to 20,000 ng/ml for the plasma and brain samples, respectively.
Pharmacodynamic Studies
Surgical Procedures. The surgical and microdialysis procedures followed a previously published protocol with minor modifications (Baumann et al., 2005) . In brief, rats were anesthetized with i.p. administration of a mixture of 100 mg/kg ketamine and 20 mg/kg xylazine. Catheters made of Silastic Medical Grade tubing (Dow Corning, Midland, MI) were then implanted in the right external jugular vein of the anesthetized rats. Subsequently, rats were placed in a stereotaxic apparatus where craniotomy was performed followed by implantation of plastic guide cannulae (CMA 12; CMA Microdialysis, Acton, MA) above the NAc at the following coordinates: anterior-posterior, ϩ1.6 mm and medial-lateral, Ϫ1.7 mm from bregma; and dorsal-ventral, Ϫ6.0 mm from dura with a flat skull (Paxinos and Watson, 1986) . The guide cannulae were cemented in place with three stainless steel screws and dental acrylic. After the surgery, the rats were placed in separate cages, and they were allowed free access to food and water for a minimum of 5 days of postsurgical recovery.
In Vivo Microdialysis. On the night before the experiment, CMA/12 microdialysis probes (2-ϫ 0.5-mm exchange surface; CMA Microdialysis) were attached to the microdialysis inflow and outflow tubing and perfused with aCSF at a flow rate of 1 l/min, pumped using CMA 400 syringe pump (CMA Microdialysis). After a short period of in vitro probe perfusion, rats were lightly anesthetized with the ultrashort-acting barbiturate methohexital at 5 mg/kg i.v., and a probe was inserted into the guide cannula of each rat. A plastic collar was placed around the neck of each rat and the animal was then placed in a Plexiglas chamber (Coulbourn Instruments, Allentown, PA). The animals were allowed free movement in the chambers while connected through tethering systems attached to their plastic collars. After insertion of the dialysis probes, perfusion with the aCSF continued overnight and afterward throughout the experiment at a flow rate of 1 l/min. On the next morning, four dialysate samples were collected for each animal to determine the baseline dopamine level and to ensure its stability. The rats were then administered vehicle [20% (2-hydroxypropyl)-␤-cyclodextrin; 1 ml/kg], 5 mg/kg cocaine, 5 or 10 mg/kg 3Ј-Cl BZT, or 5 or 10 mg/kg 4Ј,4Љ-diCl BZT via the jugular vein catheter. The selected doses were in agreement with the studied doses in the pharmacokinetic studies as well as the behaviorally active doses of these drugs, while taking into account the route of administration. The dialysate samples were collected at 10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 360, 540 , and 720 min or until dopamine returned to its basal value. Less frequent sampling scheme that covered the whole study duration was adapted for the vehicle study (10, 30, 60, 120, 240, 360, 540, and 740 min) . Dialysate collection took place throughout the 10-min preceding each sampling time and the reported sampling times are corrected for the lag caused by the outlet tubing and probe dead volumes. The dialysate samples were immediately analyzed for their dopamine content using HPLC with electrochemical detection. At the end of the microdialysis experiments, animals were returned to their housing, and they were allowed free access to food and water until euthanized by CO 2 asphyxiation. Once the animals were euthanized, the brains were removed from the skulls and stored in 10% formalin. The brains were sectioned on a cryostat, and the sections were mounted on glass slides followed by verification of the probe tip placement within the NAc by visual inspection according to the atlas of Paxinos and Watson (1986) . Rats with incorrect probe placement were excluded from the data analysis.
HPLC Analysis of the Dialysate Samples. Samples were analyzed for dopamine content by HPLC with electrochemical detection as described previously (Baumann et al., 2005) with minor modifications. The mobile phase consisted of 150 mM monochloroacetic acid, 1.5 mM sodium octane sulfonic acid, 145 mM sodium hydroxide, 215 M disodium EDTA, 6% (v/v) methanol and 6% (v/v) acetonitrile (final pH 5.3). The mobile phase was pumped at a flow rate of 60 l/min. The HPLC system consisted of an ISCO 260 D syringe pump (ISCO, Lincoln, NE), BAS model LC-4C amperometric detector (BAS Bioanalytical Systems, West Lafayette, IN), and BAS UniJet microbore analytical column (C18, 100-ϫ 1 mm, 5 M; BAS Bioanalytical Systems). The working glassy carbon electrode was set at ϩ650 mV relative to Ag/AgCl reference electrode. The signal filter and the range were set to 0.1 Hz and 0.5 nA, respectively. The injection volume was 8 l. The calibration curves for dopamine were linear in the range of 0.1 to 5 ng/ml (r 2 Ն 0.996) without any interfering peaks.
Data Analysis
Pharmacokinetic Data Analysis. The destructive sampling data obtained from the pharmacokinetic study of 3Ј-Cl BZT were initially analyzed by the naive averaging method to determine the appropriate model and to derive initial parameter estimates for the population analysis. The plasma concentrations from the three animals at each time point for each dose level were averaged. The average concentrations versus time data were then used for compartmental modeling using WinNonlin version 4.1 software (Pharsight, Mountain View, CA). Various compartmental models were evaluated to determine the most appropriate model. Subsequently, nonlinear mixed effect modeling was conducted using NONMEM version 5, level 1.1 (GloboMax LLC, Hanover, MD). This approach has been shown previously to result in less biased estimates of the structural model parameters than the naive pooling of the data in destructive sampling designs (Hing et al., 2001) . The data from the two dose levels (data from 42 animals) were compiled and analyzed. The final parameter estimates from the naive averaging analysis were used as initial estimates for the population analysis. Based on the results from the naive averaging analysis, the population analysis started with a two-compartment structural model. Interanimal variability in the pharmacokinetic parameters was estimated using an exponential error model as follows: where i is the proportional difference between the hypothetical true parameter estimate of the ith animal (P i ) and the typical population parameter value (TVP), and i is assumed to be normally distributed with a mean of zero and a variance of 2 . The residual error (which includes model mis-specification, intra-animal variability as well as errors in dosing, sampling times, and sample analysis) was described using a proportional error model as follows:
where Y obs is the observed plasma concentration, Y pred is the model predicted plasma concentration, and is a normally distributed parameter with a mean of zero and variance of 2 . The analysis was performed using the first-order estimation method. The final model was determined based on inspection of goodness of fit plots, precision of parameter estimates, and the value of the objective function. In addition, the likelihood ratio test (␣ ϭ 0.05) was used as a selection criterion between rival hierarchical models (Sheiner and Beal, 1981) . The brain-to-plasma partition coefficient (R i ) was calculated as a measure of brain uptake according to the following formula:
where AUC 0 -inf (brain) and AUC 0 -inf (plasma) are the area under the naive-averaged observed brain and plasma concentrations versus time curves, respectively. The AUC 0 -inf was calculated using WinNonlin noncompartmental analysis by applying the log-linear trapezoidal rule. Pharmacodynamic Data Analysis. For the microdialysis experiments, the brain dialysate dopamine level in each sample (uncorrected for probe recovery) was expressed as a percentage of the mean basal dopamine values. The mean basal dopamine value for each rat was calculated as the mean of dopamine concentrations in the four samples immediately preceding the drug or vehicle injections. For each treatment group, brain dialysate DA levels at the different times points were compared by one-way analysis of variance (ANOVA) with repeated measures over time followed by Dunnett's post hoc analysis with time 0 as control (␣ ϭ 0.05). In addition, the two doses of each of the chloro-analogs were compared using a two-factor (drug dose and time) ANOVA with repeated measures over time. All statistical analyses were conducted using GraphPad Prism version 4.00 for Windows (GraphPad Software Inc., San Diego, CA).
Pharmacodynamic Modeling. The concentrations of 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT were not determined at the site of action (the nucleus accumbens); therefore, the plasma concentrations were used for the pharmacodynamic modeling. The effect-time profiles of 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT were delayed relative to their plasma profiles. Three pharmacodynamic models were considered to account for this time delay: 1) effect compartment model, which assumes slow equilibration between the plasma and the biophase (Sheiner et al., 1979) ; 2) indirect response model, with inhibition of output as initially described by Dyneka et al. (1993) and previously applied in our laboratory for modeling the pharmacodynamics of 3␣-[bis(4Ј-fluorophenyl)methoxy] tropane (AHN1-005) and N-allyl-3␣-[bis(4Ј-fluorophenyl) methoxy]tropane (AHN 2-005) (Raje et al., 2005) ; and 3) slow equilibration between the free drug, free DAT and drug-DAT complex, a modified version of a kinetic binding model reported previously for modeling the effects of reversible proton pump inhibitors (Abelö et al., 2001) . Even though we did not have measurements for the drugs concentrations at the NAc, the brain uptake data indicated that slow equilibrium between the plasma and NAc is unlikely; consequently, this model was excluded. Conversely, the indirect response model does not account for the possible differences in interaction with DAT. Consequently when the indirect response model was applied, the model interpreted the difference in the pattern of DA elevation between 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT as differences in the rate constants for production and loss of dopamine (data not shown), which are characteristics of the biological system and should not differ based on the drug. Consequently, the indirect response model was also excluded, even though it provided reasonable fits to the data. Therefore, the DAT kinetic binding model was used to model the inhibition of DA uptake by 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT.
Because DA is mainly cleared from the synaptic cleft via uptake by DAT, the extracellular level of DA is assumed to be inversely proportional to the free fraction (unblocked by the BZT analogs) of the dopamine transporters (FDAT) as described by the following equation:
In absence of the BZT analogs, FDAT ϭ 1; consequently, the extracellular DA level equals the baseline value. When the analogs bind to the DA transporters, the free fraction of the transporters decreases, and the extracellular DA level accordingly increases. The rate of change of the fraction of the free transporters as a function of the plasma concentration of the analogs (Cp) can be described using the following equation:
where K on is the rate constant for association of the drug and DAT, K off is the rate constant for the dissociation of the drug from DAT, and ODAT is the fraction of the DA transporters occupied or blocked by the BZT analogs. The model assumes that the total number of transporters (drug free ϩ drug occupied) is constant during the time interval of the microdialysis experiment. Consequently, the rate of change of the fraction of the occupied transporters, ODAT, can be described using the following equation:
Equations 4 to 6 were coded in NONMEM version 5 using AD-VAN8 TRANS1 TOL ϭ 5 NONMEM subroutines. The binding model was regressed to the microdialysis data from the two dose levels tested for each drug (data from 10 animals for 3Ј-Cl BZT and 12 animals for 4Ј,4Љ-diCl BZT). Because the plasma concentrations of the BZT analogs were not measured in the same animals in which the microdialysis experiments were conducted, the mean population pharmacokinetic parameters determined in the current study for 3Ј-Cl BZT and in a previous study for 4Ј,4Љ-diCl BZT (Othman et al., 2007) were used to simulate the plasma concentrations for a typical animal at the times of measurement of DA for each dose tested. The plasma concentrations for all the animals were then fixed to these typical values, and they were used as input for the pharmacodynamic modeling. The first-order conditional estimation procedure was used in the pharmacodynamic analysis, because a rich sampling design was adapted in these studies. The DA levels were modeled as ratios to baseline (instead of percentages) to facilitate the mathematical computations, and then they were backtransformed to percentages. The equilibrium dissociation constant (K d ) was determined as a secondary parameter from the ratio between K off and K on . Additive, proportional and exponential statistical error models were evaluated to describe the interanimal variability in the pharmacodynamic parameters as well as the residual variability. The final model was determined based on the same criteria described above for the pharmacokinetic analysis.
Results
Pharmacokinetics of 3-Cl BZT. Figure 2A represents the observed and the population predicted plasma concentrations of 3Ј-Cl BZT upon i.v. administration to male SpragueDawley rats at two dose levels (5 and 10 mg/kg). Figure 2B . The interanimal variability in CL and V p were not significantly different from zero based on the likelihood ratio test (p Ͼ 0.05), and they were omitted from the model. Due to the destructive sampling design, precise estimation of the residual random error was not possible. Consequently, the residual error was fixed to 10.7% based on a sensitivity analysis, and the final selected value was the value resulting in the lowest objective function and the highest precision in estimation of interanimal variability. The 10.7% residual random error was comparable with the estimated or fixed values for previously studied BZT analogs using identical experimental technique (Othman et al., 2007) . Figure 3 represents the relevant diagnostic plots for the final population pharmacokinetic model for 3Ј-Cl BZT, and it indicates that the model described the pharmacokinetics of 3Ј-Cl BZT without any systematic bias. The population pharmacokinetic parameters along with their associated interanimal variability and the precision of the parameter estimates (expressed as coefficient of variation) are reported in Table 1 . The secondary pharmacokinetic parameters of interest along with their associated standard deviation were calculated from empirical Bayes estimates of the animal-specific parameters provided by NONMEM. These secondary parameters are reported in Table 2 in comparison with the previously reported parameters for 4Ј-Cl BZT, 4Ј,4Љ-diCl BZT, and cocaine (Othman et al., 2007) . The calculated pharmacokinetic parameters for 3Ј-Cl BZT based on the population analysis were in good agreement with results of the assumptionfree noncompartmental analysis (data not shown). The doseexposure relationship for 3Ј-Cl BZT was linear in plasma over the dose range studied ( Fig. 2A ; Table 2 ; data from noncompartmental analysis). However, the brain exposure observed at the 10-mg/kg dose was about 3.4-fold that of the 5-mg/kg dose (Fig. 2B) . This resulted in a higher brain-toplasma partition coefficient for the 10-mg/kg dose compared with the 5-mg/kg dose of 3Ј-Cl BZT ( Table 2 ). The significance of this difference could not be assessed given the destructive sampling design and the naive averaging of the brain data. 3Ј-Cl BZT had the shortest plasma and brain elimination half-lives (t 1/2 ) among all the chloro-BZT analogs ( Table 2) .
Effect of Cocaine, 3-Cl BZT, and 4,4؆-diCl BZT on the NAc DA Levels. Figure 4 shows the effects of i.v. administration of the vehicle [20% (2-hydroxypropyl)-␤-cyclodextrin; 1 ml/kg], 5 mg/kg cocaine, 5 or 10 mg/kg 3Ј-Cl BZT, and 5 or 10 mg/kg 4Ј,4Љ-diCl BZT on the levels of DA in the dialysate samples from the NAc of Sprague-Dawley rats. Injection of the vehicle had no effect on the DA levels, and the levels remained stable throughout the time course of the experiment (Fig. 4A) . Cocaine was used as a positive control at the 5-mg/kg dose. Administration of cocaine resulted in a rapid and significant elevation of DA (ANOVA; p Ͻ 0.0001). The maximal increase of DA reached 1011% of the basal values 10 min postdose (first sampling time). The DA levels remained significantly elevated during the 20 min after administration (post hoc; p Ͻ 0.05), and they returned back to the basal values within 2 h (Fig. 4A) .
Administration of 5 or 10 mg/kg 3Ј-Cl BZT resulted in a significant elevation of the DA levels at each dose (ANOVA; p Ͻ 0.0001). The maximal increase of DA was 441 and 643% of the basal values at the 5-and 10-mg/kg doses, respectively, and it was observed 20 to 30 min postdose (Fig. 4B) . The DA levels were significantly elevated above the basal values throughout the 4 h after administration (post hoc; p Ͻ 0.05). After reaching the peak, the DA levels declined at a slower rate than that observed with cocaine, and they returned to basal values around 6 h postdose. When the effects of the two doses of 3Ј-Cl BZT were compared using a two-way ANOVA, there was a significant effect of dose, time, and dose ϫ time interaction (p Ͻ 0.05).
Administration of 5 or 10 mg/kg 4Ј,4Љ-diCl BZT resulted in a significant elevation of the DA levels at each dose (ANOVA; p Ͻ 0.0001). The increase in DA was relatively slow with a maximum of around 204 and 275% of the basal values for the 5-and 10-mg/kg doses, respectively (Fig. 4C) . The DA levels reached their maximal values 2 to 4 h postdose, and they remained significantly elevated for up to 9 h postdose for the 5-mg/kg dose and until the experiment ended at 12 h for the 10-mg/kg dose (post hoc; p Ͻ 0.05). When the effects of the two doses of 4Ј,4Љ-diCl BZT were compared using a two-way ANOVA, there was a significant effect of dose, time, and dose ϫ time interaction (p Ͻ 0.05).
Pharmacodynamic Modeling. The effect versus time profiles for 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT were delayed relative to the plasma concentration versus time profiles of these analogs (Fig. 5) . In addition, 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT have shown significant differences in their pharmacodynamic patterns in terms of rate of elevation of DA level, duration of elevation, and rate of decline. This suggested possible differences in the interaction of these analogs with DAT. Consequently, to be able to characterize these differences, a kinetic binding model at DAT was used for describing the pharmacodynamics of 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT. In this model, the drug effects are governed by the drug concentration as well as by the association and dissociation kinetics with DAT. The relevant diagnostic plots for the final pharmacodynamic models for 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT are presented in Fig. 6 . The scatter plots of the observed versus population and individual predicted dialysate dopamine levels (Fig. 6, A, B, D , and E) and the dose stratified observed and mean population predicted versus time profiles (Fig. 7) indicated that the models adequately described the pharmacodynamics of 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT. In addition, the scatter plots of the weighted residuals versus time did not show any significant pattern, indicating the lack of significant bias in the fit to the data (Fig. 6, C and F) . In addition, the majority of weighted residuals were within Ϯ 3 S.D. of the mean (Fig. 6, C and F) . The population pharmacodynamic parameters along with their associated interanimal variability and the precision of the parameter estimates (expressed as coefficient of variation) are reported in Table 3 . The pharmacodynamic parameters were estimated with adequate precision. Precise estimation of the baseline for 4Ј,4Љ-diCl BZT was not possible, most probably because the DA levels remained elevated after drug administration during the 12-h observation period. Therefore, the baseline was fixed in the model to its known value (i.e., 100%). The interanimal variability in the pharmacodynamic parameters was best described with an exponential pharmacostatistical model. The estimation of interanimal variability in the pharmacodynamic parameters was relatively imprecise; most probably due to the relatively small sample sizes. As indicated previously, the mean population pharmacokinetic parameters were used for the pharmacodynamic analysis because the pharmacokinetic and pharmacodynamic experiments were not conducted in the same set of animals. Therefore, the estimates for interanimal variability in the pharmacodynamic parameters should be interpreted with caution, because they may be confounded with the pharmacokinetic variability.
The model estimates indicated significant difference between 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT in terms of interaction with DAT with 3Ј-Cl BZT having significantly higher apparent association and dissociation rate constants. In addition, 3Ј-Cl BZT had lower apparent K d value (K off /K on ratio) compared with that of 4Ј,4Љ-diCl BZT (Table 3) .
Discussion
Behavioral studies of the chloro-BZT analogs revealed significant differences in their cocaine-like activity, and consequently, in their preclinical abuse liability. These differences seemed to contradict the dopamine hypothesis of psychostimulant abuse; given the similarity among these analogs in their in vitro affinities to DAT, and in their in vitro potencies as DA uptake inhibitors. Because of the shared main mechanism of action between the chloro-BZT analogs and cocaine, Fig. 3 . Diagnostic plots for the population analysis of the plasma concentrations of 3Ј-Cl BZT (n ϭ 42 rats) conducted using NONMEM. The data from the two dose levels tested (5 and 10 mg/kg i.v.) were combined before the analysis. A, population predicted versus observed plasma concentrations. B, individual animal predicted versus observed plasma concentrations. C, weighted residuals versus time plot. The dashed lines in the weighted residual plot represent Ϯ 3 S.D. V c , volume of the central compartment; Q, intercompartmental clearance. a The IAV estimates should be interpreted with caution, given the difficulty in fully resolving the IAV from the residual random error with the destructive sampling design.
b -, parameter values not significantly different from zero (p Ͼ 0.05) based on the likelihood ratio test (the objective function was compared when the parameter was freely estimated and when it was fixed to zero).
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at ASPET Journals on April 30, 2017 jpet.aspetjournals.org it was of considerable interest to delineate the causes of the behavioral differences of this class of compounds (Tolliver et al., 1999; Woolverton et al., 2000 Woolverton et al., , 2001 Katz et al., 2001) , because it may improve the overall understanding of the determinants of abuse potential of DA uptake inhibitors, which is essential for informed design of low-risk substitute therapeutics for treatment of cocaine abuse.
Several reports indicated that 3Ј-Cl BZT possessed some behavioral effects similar to cocaine (Kline et al., 1997; Woolverton et al., 2000 Woolverton et al., , 2001 Katz et al., 2001) . Conversely, 4Ј,4Љ-diCl BZT was almost totally devoid of these cocaine-like behavioral patterns . The results of the present study show remarkable quantitative and qualitative differences among 3Ј-Cl BZT, 4Ј,4Љ-diCl BZT, and cocaine in their effects on the extracellular DA level in the NAc, the reward center responsible for the reinforcing effects of most drugs of abuse.
3Ј-Cl BZT resulted in a rapid DA elevation (DA T max ϭ 20 -30 min) that although slower than that of cocaine (DA T max ϭ 10 min), still it was much faster than the rate of DA elevation observed with 4Ј,4Љ-diCl BZT (DA T max ϭ 120 -240 min) (Fig. 4) . These differences in onset of DA elevation are in good agreement with the rate hypothesis of psychostimulant abuse, which postulates that drugs of slower onset of action are less likely to be abused than drugs of faster onset (Gorelick, 1998) . In addition, the present results agree with the evidence that the rate at which DA increases is an essential variable for determining the reinforcing effects of most drugs of abuse (Volkow, 2006) . The differences in the rate of DA elevation observed in the present study cannot be accounted for by difference in the rate at which the drugs reached the site of action for two reasons. First, the microdialysis studies were conducted using the i.v. route, which excludes any possible difference in the absorption rate from TABLE 2 Secondary pharmacokinetic parameters (calculated from the NONMEM empirical Bayes estimates of the individual animal-specific pharmacokinetic parameters) and brain-to-plasma partition coefficient and brain t (based on the noncompartmental analysis performed with WinNonlin) for 3Ј-Cl BZT in comparison with previously published data for 4Ј-Cl BZT, 4Ј,4Љ-diCl BZT, and cocaine (Othman et al., 2007) (Othman et al., 2007) . jpet.aspetjournals.org the site of administration. Second, the brain uptake studies for cocaine (Raje et al., 2003) , 4Ј,4Љ-diCl BZT (Othman et al., 2007) , and 3Ј-Cl BZT indicated that the three drugs were detected in the brain at their highest concentrations within 2 to 5 min of administration, which excludes the difference in brain entry rate as a cause for the difference in rate of DA elevation. This conclusion is further supported by previous microdialysis studies that indicated that even direct delivery of 4Ј-Cl BZT into the NAc by local infusion resulted in delayed onset of DA elevation relative to local infusion of cocaine (Tolliver et al., 1999) . Based on that observation, Tolliver et al. (1999) suggested that the BZT analogs bind to DAT at slower rate than cocaine, a hypothesis that was later supported by in vivo DAT occupancy studies with a series of fluoro-BZT analogs (Desai et al., 2005a,b) . In one of these studies, the two fluoro-BZT analogs AHN 1-055 and AHN 2-005 showed comparable and slower rates of association with DAT relative to cocaine (Desai et al., 2005a) . When these two analogs were compared using microdialysis in our laboratory, AHN 1-055 and AHN 2-005 demonstrated almost superimposable DA profiles (Raje et al., 2005) . By analogy, if the rates of association of 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT were not different, administration of these analogs would be expected to result in similar DA elevation patterns. Therefore, it seems that the rate of association with DAT differs significantly among the chloro-BZT analogs, with 4Ј,4Љ-diCl BZT most probably having much slower rate of DAT association relative to 3Ј-Cl BZT. The extent of DA elevation was also consistently different across the three drugs. At an i.v. dose of 5 mg/kg, cocaine resulted in about 10-fold increase in extracellular DA; in agreement with a report by Baumann et al. (1994) , which showed, using a similar microdialysis technique, that 3 mg/kg i.v. cocaine resulted in a 6-fold increase in the DA levels. In contrast to cocaine, 3Ј-Cl and 4Ј,4Љ-diCl BZT at the 5-mg/kg dose resulted in 4.4-and 2-fold increase in DA, respectively. At this dose, the brain uptake, as measured by the brain-to-plasma partition coefficients, for cocaine, 3Ј-Cl and 4Ј,4Љ-diCl BZT was 2.1, 5.3, and 4.5, respectively. These results indicate that the differences in the extent of DA elevation by the three drugs most probably stem from differences in their in vivo potency or intrinsic activity rather than from differences in their brain exposure. The fact that even by doubling the dose, the DA elevation observed with 3Ј-Cl and 4Ј,4Љ-diCl BZT (6.4-and 2.8-fold, respectively) was significantly lower than the 10-fold observed with cocaine at half the dose further supports this conclusion.
In the present study, 3Ј-Cl BZT has shown plasma and brain elimination half-lives around 1.9 and 1.5 h, respectively. These values were the shortest and closest to cocaine among all the BZT analogs tested so far (Raje et al., 2003; Othman et al., 2007 ; unpublished data from our laboratory). Moreover, the relatively short half-lives of 3Ј-Cl BZT contrast markedly with the long plasma and brain elimination halflives of 4Ј,4Љ-diCl BZT (Table 2 ). In agreement with the difference in the rate of elimination from the body, the rate of decline of DA after the peak was different across the three drugs, with cocaine showing very fast DA decline followed by 3Ј-Cl BZT, which maintained elevated levels for about 6 h. In contrast, 4Ј,4Љ-diCl BZT showed sustained DA elevation during the 12-h time course of the experiment (Fig. 4) . Several studies of psychostimulant drugs indicated that the timing of drug-seeking responses in experimental animals is dependent on the fluctuations in the extracellular DA concentrations; with higher probability of drug seeking when the DA concentrations fall near certain trigger points (Wise et al., 1995; Ranaldi et al., 1999) . Therefore, it seems that the differences in the patterns of decline in DA might also explain, in part, the observed differences among cocaine and the chloro-compounds in the rates of self-administration in rhesus monkeys (Woolverton et al., 2000 . It is noteworthy that even though the rank order for duration of DA elevation (cocaine Ͻ 3Ј-Cl BZT Ͻ Ͻ 4Ј,4Љ-diCl BZT) matches the pattern of their difference in the plasma and brain elimination half-lives (Table 2) , it still seems that the dissociation of 4Ј,4Љ-diCl BZT from DAT was slower than 3Ј-Cl BZT, which resulted in sustained DA elevation for 4Ј,4Љ-diCl BZT even though its systemic concentrations were decreasing with time (Fig. 5) .
The effect-time profiles of 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT were delayed relative to their plasma profiles. A kinetic binding model that assumes slow equilibration between the free drug, free DAT, and drug-DAT complex was used to describe the pharmacodynamics of 3Ј-Cl BZT and 4Ј,4Љ-diCl BZT. The parameter estimates from the model indicated that 3Ј-Cl BZT binds with DAT approximately 5 times faster than 4Ј,4Љ-diCl BZT, resulting in the difference in onset of DA elevation. In addition, the dissociation of 3Ј-Cl BZT was ϳ3-fold faster relative to 4Ј,4Љ-diCl BZT, resulting in observed difference in duration of DA elevation and rate of DA decline. Moreover, the K d values (K off /K on ) indicated that 4Ј,4Љ-diCl BZT seems to have lower apparent in vivo affinity to DAT than 3Ј-Cl BZT, which may be responsible for the difference between these two analogs in terms of maximal DA elevation.
In conclusion, the present data make it clear that the behavioral profiles of the chloro-BZT analogs are supportive rather than contradictory to the dopamine hypothesis, and that these analogs differ significantly in their in vivo dopa -TABLE 3 Population pharmacodynamic parameters for 3Ј-Cl BZT (n ϭ 10) and 4Ј,4Љ-diCl BZT (n ϭ 12) along with their associated interanimal variability using the DAT binding model minergic patterns, which account for the differences in abuse liability in a way that corroborates the rate hypothesis of drug abuse. A substitute therapeutic agent that possess a pharmacodynamic profile similar to 4Ј,4Љ-diCl BZT may be helpful for patients during withdrawal from cocaine use by correcting the hypodopaminergic state underlying the dysphoria and anhedonia experienced during this phase (Volkow et al., 2002) . At the same time, due to its slow onset and long duration of action, this substitute agent will have minimal risk of abuse on its own. An attractive feature of some BZT analogs, such as 4Ј,4Љ-diCl BZT, is their minimal abuse potential even when administered through the i.v. route, unlike methylphenidate, for example, that has shown low abuse liability upon oral administration, whereas it is abused using the i.v. route (Parran and Jasinski, 1991) . A drug that is devoid of abuse potential regardless of the route of administration and dosage form will definitely be favored taking in account the vulnerable nature of the target population.
